Publications by authors named "Nhieu Thi Le"
Article Synopsis
- Osimertinib targets and inhibits the epidermal growth factor receptor (EGFR) in cancer cells, leading to cell death and reduced tumors, making it a key treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
- The ADAURA study compared the effects of osimertinib to a placebo in patients with surgically removed early-stage (IB-IIIA) EGFR-mutated NSCLC, showing that those on osimertinib had longer disease-free survival.
- Recent results reveal that osimertinib significantly improves overall survival, with a 51% lower risk of death for patients treated with it compared to the placebo group.
Background: Among patients with resected, epidermal growth factor receptor ()-mutated, stage IB to IIIA non-small-cell lung cancer (NSCLC), adjuvant osimertinib therapy, with or without previous adjuvant chemotherapy, resulted in significantly longer disease-free survival than placebo in the ADAURA trial. We report the results of the planned final analysis of overall survival.
Methods: In this phase 3, double-blind trial, we randomly assigned eligible patients in a 1:1 ratio to receive osimertinib (80 mg once daily) or placebo until disease recurrence was observed, the trial regimen was completed (3 years), or a discontinuation criterion was met.